Atopic Dermatitis

A new study found that the Worst Itch Numeric Rating Scale is a valid and reliable instrument to capture itch data of patients with prurigo nodularis.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

Higher dietary sodium intake was associated with a higher risk for current atopic dermatitis, suggesting that a sodium-restricting diet may be a helpful intervention for disease management, according to a study.

Vaccinations can be safe and effective during dupilumab treatment, according to the consensus of a panel published in Annals of Allergy, Asthma & Immunology.

Due to medical advancements, researchers are calling for an update to the U.S. Department of Defense’s policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military, according to a study.

Adults treated with amlitelimab showed sustained improvement in their moderate to severe atopic dermatitis over the span of 28 weeks, Sanofi announced in a press release.

The FDA has cleared InnoCare Pharma’s investigational new drug application for ICP-332, according to a press release.

In order to better manage symptoms of atopic dermatitis, health care professionals must consider aggravating factors and systemic immunotherapy, according to a study published in the Chinese Medical Journal.